Variable | Without relapse, n = 20 | With relapse, n = 9 | P value |
---|---|---|---|
Baseline demographic | |||
 Age at diagnosis, years | 67 (55–78) | 75 (65–80) | 0.27 |
 Male, n (%) | 11 (58) | 2 (22) | 0.070 |
 PR3-ANCA+ GPA, n (%) | 4 (20) | 3 (33) | 0.65 |
 MPO-ANCA+ GPA, n (%) | 3 (15) | 2 (22) | 0.64 |
 ANCA− GPA, n (%) | 1 (5) | 0 (0) | 0.38 |
 MPO-ANCA+ MPA, n (%) | 12 (60) | 4 (44) | 0.44 |
 BVAS | 11 (8.3–16) | 12 (8.5–16) | 0.74 |
Organ involvement | |||
 Ear, nose, throat, n (%) | 7 (35) | 6 (67) | 0.11 |
 CNS, n (%) | 4 (20) | 3 (33) | 0.43 |
 PNS, n (%) | 2 (10) | 3 (33) | 0.13 |
 Kidney, n (%) | 10 (50) | 2 (22) | 0.15 |
 ILD, n (%) | 11 (55) | 5 (56) | 0.98 |
Laboratory tests | |||
 ESR, mm/h | 102 (48–125) | 106 (43–127) | 0.77 |
 WBC, × 103 cells/μL | 9.9 (7.1–14) | 9.0 (6.3–12) | 0.46 |
 Hemoglobin, g/dL | 11 (9.8–13) | 11 (9.4–13) | 0.51 |
 Platelet, × 104 cells/μL | 33 (26–42) | 35 (19–40) | 0.51 |
 CRP, mg/dL | 5.2 (1.6–8.5) | 8.3 (0.8–11) | 0.57 |
 IgG, mg/dL | 1.8 (1.3–2.0) | 1.8 (1.2–2.3) | 0.55 |
 RF, IU/L | 56 (26–188) | 37 (15–93) | 0.28 |
 MPO/PR3-ANCA, IU/L | 79 (19–276) | 40 (14–51) | 0.14 |
PSL dose | |||
 Initial PSL dose, mg/day | 50 (40–60) | 35 (30–58) | 0.28 |
 PSL dose at week 24, mg/day | 10 (9–13) | 17 (11–35) | 0.026 |
 PSL dose at week 52, mg/day | 7 (5–9) | 10 (10–16) | 0.0071 |
Immunosuppressive drugs | |||
 Induction therapy | IVCY, 7 (35); RTX, 5 (25); AZA, 8 (40) | IVCY, 3 (33); RTX, 3 (33); AZA, 1 (11); MTX, 1 (11) | – |
 Maintenance therapy until relapse | RTX, 5 (25); AZA, 10 (50); MTX, 1 (5); Tac, 2 (10) | RTX, 1 (11); AZA, 2 (22); MTX, 1 (11) | – |
 Reinduction therapy | – | IVCY, 3 (33); RTX, 2 (22) | – |
 Maintenance therapy after reinduction therapy | – | RTX, 1 (11); AZA, 2 (22); Tac, 1 (11) | – |
Outcome | |||
 Severe infection, n (%) | 4 (20) | 6 (67) | 0.015 |
 Death, n (%) | 1 (5) | 1 (11) | 0.56 |